Compare ConocoPhillips (COP) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Novavax Inc — how do they compare? ConocoPhillips trades at $133.15 (market cap $161.21B), while Novavax Inc trades at $11.1 (market cap $1.82B). The key difference: ConocoPhillips is far larger — about 88.6× Novavax Inc's market cap, and ConocoPhillips pays a 2.5% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Novavax Inc for 59 Days on average.
| COP | NVAX | |
|---|---|---|
Market Cap | $161.21B | $1.82B |
Volume | 6,058,403 | 6,198,505 |
Sector | Energy | Health |
52-Week High | $141.22 | $12.56 |
52-Week Low | $85.66 | $6.22 |
Typical Hold Time | 79 Days | 59 Days |
Enterprise Value | $176.81B | $1.39B |
Dividend Yield | 2.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $129.84, up 0.38% today, with strong technical momentum and bullish moving average signals. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026, with revenue growth from $58.94B in 2025 to projected $63.3B in 2026. Recent developments include a 20-year LNG supply agreement with Venture Global and potential asset sales in Norway and the UK, signaling strategic portfolio optimization.
COP presents a compelling investment case with solid fundamentals—P/E of 17.75, ROE of 14.14%, and robust cash flow—supported by a 75% analyst buy rating and $154.75 consensus price target. Key risks include geopolitical exposure in the Middle East, oil price volatility, and execution of asset sales. The stock's current level near resistance at $130 suggests near-term consolidation potential amid bullish long-term prospects.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
